Geron Stock Soars 11%, Adding $64 Million, As Rytelo Sales Push It To A Profit

The blood-cancer drugmaker posted a small third-quarter profit on Rytelo growth and trimmed its 2026 operating expense guidance.

Share
Geron Stock Soars 11%, Adding $64 Million, As Rytelo Sales Push It To A Profit

Geron shares climbed 10.75% to $1.03 in Wednesday trading, as of 10:23 a.m. ET, adding about $64 million in market value after the blood-cancer drugmaker reported a third-quarter profit and lowered its 2026 spending outlook.

Rytelo carries the quarter

Geron sells the telomerase inhibitor Rytelo for lower-risk myelodysplastic syndromes. Rytelo revenue reached $60.1 million, up 5% from the prior quarter, with about 1,700 ordering accounts.

The company lowered its 2026 operating expense guidance to $220 million to $230 million. It ended the quarter with $339 million in cash, cash equivalents, restricted cash and marketable securities.

Rytelo is approved in the US for adults with transfusion-dependent anemia from lower-risk myelodysplastic syndromes, a group of blood cancers. Geron is also testing imetelstat in myelofibrosis and other blood cancers.

A turn after a rough year

The profit follows a net loss of $16.7 million for the quarter ended June 30. Wednesday's move put the stock on pace for its biggest one-day gain since August 5, when it rose 21.6%.

Even so, shares were down about 29% year to date at Tuesday's close, while the S&P 500 was up about 11%. The stock had fallen 23% over the prior month and sat 52% below its highest close of the past year, set February 24.

Europe is next

Geron is expanding a gated European launch. Rytelo is expected to be available in Germany by the end of 2026, with France targeted for 2027.

Germany by the end of 2026 and France in 2027 are the next markets on Geron's European launch list.

Sources

More on Geron

All Geron (GERN) coverage →